Monohydrazide Compounds for Drug-Resistant A. Baumannii
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The emergence of multidrug-resistant Acinetobacter baumannii strains poses a significant challenge due to their innate and acquired antibiotic resistance, making existing antibiotics ineffective and difficult to treat infections caused by this bacterium, particularly in healthcare settings.
Innovation Solution
Development of monohydrazide compounds with a unique structural class that exhibit high potency against multidrug-resistant A. baumannii strains, inhibit growth in biofilms, and do not induce resistance, while maintaining low mammalian cytotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antibiotics are used to treat A. baumannii infections, then treatment is attempted, but antibiotic resistance renders them ineffective
Solution Approach 1:
The patent employs parameter changes by developing a series of monohydrazide compounds with varying molecular structures, substituent groups, and chemical properties to overcome antibiotic resistance. The compounds are designed with different R groups and molecular weights to achieve optimal activity against resistant A. baumannii strains while maintaining selective toxicity
Solution Approach 2:
The patent creates composite chemical structures by combining the monohydrazide core with various aromatic rings, heterocyclic groups, and substituent patterns. These composite molecular structures provide diverse mechanisms of action that bypass resistance mechanisms developed against conventional antibiotics
2Reliability
If high concentrations of antibiotics are used to overcome resistance, then bacterial growth is inhibited, but mammalian cytotoxicity increases
Solution Approach 1:
The patent applies local quality by designing monohydrazide compounds with specific molecular features that confer selective activity. The compounds possess structural characteristics that enable them to target bacterial-specific pathways while sparing mammalian cells, achieving high bacterial growth inhibition at concentrations that do not cause significant mammalian cytotoxicity
3Duration of action of moving object
If conventional antibiotics are used, then initial treatment may be effective, but resistance develops rapidly rendering the drugs useless
Solution Approach 1:
The patent employs preliminary action by developing monohydrazide compounds with unique mechanisms of action that have not been previously exploited by A. baumannii. The compounds are designed to prevent resistance development from the outset by targeting bacterial pathways that have not been subject to selective pressure from conventional antibiotics
Data Source
AI summary
The presently-disclosed subject matter provides a compound of Formula (I): or a pharmaceutically acceptable salt of the compound, wherein R1 is C1-4 alkyl, C1-4 alkene, or, wherein R3, R4, R5, and R6 are independently hydrogen or halogen, or R4 and R5, taken together with the atoms to which they are bound, form a 6-membered ring; and wherein X1 and X2 are independently C or N; and wherein R2 is or, wherein R7 and R8 are independently hydrogen, halogen, or C1-4 alkoxy; and the use thereof in controlling (Acinetobacter baumannii and treating A. baumannii infection.